Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q38085077

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Renewed interest in the role o ...... diffuse large B-cell lymphoma.

@en

type

Item

label

Renewed interest in the role o ...... diffuse large B-cell lymphoma.

@en

prefLabel

Renewed interest in the role o ...... diffuse large B-cell lymphoma.

@en

P1476

Renewed interest in the role o ...... diffuse large B-cell lymphoma

@en

P2093

Christopher Flowers

http://www.w3.org/2001/XMLSchema#string

Satya Das

http://www.w3.org/2001/XMLSchema#string

Zheng Shi

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

P304

2122-2130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.779687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mohammad K. Khan

Natia Esiashvili

P577

2013-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23445367

http://www.w3.org/2001/XMLSchema#string